Jump into a new fold-A homology based model for the ABCG2/BCRP multidrug transporter

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Lászloá, Laura ^a   Sarkadi, Balázs ^a,b   Hegedüs, Tamás ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHOLESTEROL; MULTIDRUG RESISTANCE PROTEIN; ISOPROTEIN; RECOMBINANT PROTEIN; SALAZOSULFAPYRIDINE;

ARTICLE; BILAYER MEMBRANE; COMPUTER MODEL; CONTROLLED STUDY; DIMERIZATION; GENETIC VARIABILITY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MUTATION; NUCLEOTIDE BINDING SITE; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; SIMULATION; AMINO ACID SEQUENCE; BINDING SITE; BIOSYNTHESIS; CHEMISTRY; DRUG RESISTANCE; ENZYME SPECIFICITY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; BINDING SITES; CHOLESTEROL; DIMERIZATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SUBSTRATE SPECIFICITY; SULFASALAZINE;

EID: 84992161913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0164426     Document Type: Article

References (73)

1. ABC Transporters-40 Years on: Springer International Publishing; 2016 2016.
2. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiological reviews. 2006; 86(4):1179-236. Epub 2006/10/04. doi: 10.1152/physrev.00037.2005 PMID: 17015488.
3. Kerr ID, Jones PM, George AM. Multidrug efflux pumps: the structures of prokaryotic ATP-binding cassette transporter efflux pumps and implications for our understanding of eukaryotic P-glycoproteins and homologues. The FEBS journal. 2010; 277(3):550-63. Epub 2009/12/08. doi: 10.1111/j.1742- 4658.2009.07486.x PMID: 19961540.
4. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nature reviews Molecular cell biology. 2009; 10(3):218-27. Epub 2009/02/24. doi: 10.1038/nrm2646 PMID: 19234479; PubMed Central PMCID: PMC2830722.
5. Locher KP. Review. Structure and mechanism of ATP-binding cassette transporters. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2009; 364(1514):239-45. Epub 2008/10/30. doi: 10.1098/rstb.2008.0125 PMID: 18957379; PubMed Central PMCID: PMC2674090.
6. Li J, Jaimes KF, Aller SG. Refined structures of mouse P-glycoprotein. Protein science: a publication of the Protein Society. 2014; 23(1):34-46. Epub 2013/10/25. doi: 10.1002/pro.2387 PMID: 24155053; PubMed Central PMCID: PMC3892297.
7. Corradi V, Vergani P, Tieleman DP. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): CLOSED AND OPEN STATE CHANNEL MODELS. The Journal of biological chemistry. 2015; 290 (38):22891-906. Epub 2015/08/01. doi: 10.1074/jbc.M115.665125 PMID: 26229102; PubMed Central PMCID: PMC4645605.
8. Ni Z, Bikadi Z, Cai X, Rosenberg MF, Mao Q. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport. American journal of physiology Cell physiology. 2010; 299(5):C1100-9. Epub 2010/08/27. doi: 10. 1152/ajpcell.00160.2010 PMID: 20739628; PubMed Central PMCID: PMC2980320.
9. Serohijos AW, Hegedus T, Aleksandrov AA, He L, Cui L, Dokholyan NV, et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(9):3256-61. Epub 2008/02/29. doi: 10.1073/pnas.0800254105 PMID: 18305154; PubMed Central PMCID: PMC2265173.
10. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the sidepopulation phenotype. Nature medicine. 2001; 7(9):1028-34. Epub 2001/09/05. doi: 10.1038/nm0901- 1028 PMID: 11533706.
11. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews Cancer. 2002; 2(1):48-58. Epub 2002/03/21. doi: 10.1038/nrc706 PMID: 11902585.
12. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug discovery today. 2008; 13(9- 10):379-93. Epub 2008/05/13. doi: 10.1016/j.drudis.2007.12.010 PMID: 18468555.
13. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature reviews Cancer. 2005; 5 (4):275-84. Epub 2005/04/02. doi: 10.1038/nrc1590 PMID: 15803154.
14. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). Journal of cell science. 2000; 113 (Pt 11):2011-21. Epub 2000/05/12. PMID: 10806112.
15. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochemical pharmacology. 2012; 83(8):1084-103. Epub 2012/01/18. doi: 10. 1016/j.bcp.2012.01.002 PMID: 22248732; PubMed Central PMCID: PMC3307098.
16. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008; 372 (9654):1953-61. Epub 2008/10/07. doi: 10.1016/S0140-6736(08)61343-4 PMID: 18834626; PubMed Central PMCID: PMC2803340.
17. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(25):10338-42. Epub 2009/ 06/10. doi: 10.1073/pnas.0901249106 PMID: 19506252; PubMed Central PMCID: PMC2700910.
18. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Science translational medicine. 2009; 1(5):5ra11. Epub 2010/04/07. doi: 10.1126/ scitranslmed.3000237 PMID: 20368174.
19. Lee JY, Kinch LN, Borek DM, Wang J, Urbatsch IL, Xie XS, et al. Crystal structure of the human sterol transporter ABCG5/ABCG8. Nature. 2016; 533(7604):561-4. Epub 2016/05/05. doi: 10.1038/ nature17666 PMID: 27144356.
20. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. International journal of cancer. 2004; 109(2):238-46. Epub 2004/01/30. doi: 10.1002/ijc.11669 PMID: 14750175.
21. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer chemotherapy and pharmacology. 2005; 56(2):161-72. Epub 2005/04/20. doi: 10.1007/s00280-004-0931-x PMID: 15838659.
22. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharmaceutical research. 2004; 21(10):1895-903. Epub 2004/11/24. PMID: 15553238.
23. Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochimica et biophysica acta. 2005; 1668(1):53-63. Epub 2005/01/27. doi: 10.1016/j.bbamem.2004.11.005 PMID: 15670731.
24. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. ClustalWand Clustal X version 2.0. Bioinformatics. 2007; 23(21):2947-8. Epub 2007/09/12. doi: 10.1093/ bioinformatics/btm404 PMID: 17846036.
25. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annual review of biophysics and biomolecular structure. 2000; 29:291-325. Epub 2000/08/15. doi: 10.1146/annurev.biophys.29.1.291 PMID: 10940251.
26. Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI. OPM: orientations of proteins in membranes database. Bioinformatics. 2006; 22(5):623-5. Epub 2006/01/07. doi: 10.1093/bioinformatics/btk023 PMID: 16397007.
27. Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013; 29(7):845-54. Epub 2013/02/15. doi: 10.1093/bioinformatics/btt055 PMID: 23407358; PubMed Central PMCID: PMC3605599.
28. Best RB, Zhu X, Shim J, Lopes PEM, Mittal J, Feig M, et al. Optimization of the Additive CHARMM All- Atom Protein Force Field Targeting Improved Sampling of the Backbone phi, psi and Side-Chain chi(1) and chi(2) Dihedral Angles. Journal of chemical theory and computation. 2012; 8(9):3257-73. doi: 10. 1021/ct3004000x PMID: ISI:000308830700029.
29. Wu EL, Cheng X, Jo S, Rui H, Song KC, Davila-Contreras EM, et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. Journal of computational chemistry. 2014; 35 (27):1997-2004. Epub 2014/08/19. doi: 10.1002/jcc.23702 PMID: 25130509; PubMed Central PMCID: PMC4165794.
30. Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, et al. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. Journal of chemical theory and computation. 2016; 12(1):405-13. Epub 2015/12/04. doi: 10.1021/acs.jctc.5b00935 PMID: 26631602; PubMed Central PMCID: PMC4712441.
31. Michaud-Agrawal N, Denning EJ, Woolf TB, Beckstein O. MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. Journal of computational chemistry. 2011; 32(10):2319-27. Epub 2011/04/19. doi: 10.1002/jcc.21787 PMID: 21500218; PubMed Central PMCID: PMC3144279.
32. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. Journal of cheminformatics. 2011; 3:33. Epub 2011/10/11. doi: 10.1186/1758-2946- 3-33 PMID: 21982300; PubMed Central PMCID: PMC3198950.
33. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and Auto- DockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry. 2009; 30(16):2785-91. Epub 2009/04/29. doi: 10.1002/jcc.21256 PMID: 19399780; PubMed Central PMCID: PMC2760638.
34. Kelly L, Pieper U, Eswar N, Hays FA, Li M, Roe-Zurz Z, et al. A survey of integral alpha-helical membrane proteins. Journal of structural and functional genomics. 2009; 10(4):269-80. Epub 2009/09/18. doi: 10.1007/s10969-009-9069-8 PMID: 19760129; PubMed Central PMCID: PMC2780624.
35. Wen PC, Verhalen B, Wilkens S, McHaourab HS, Tajkhorshid E. On the origin of large flexibility of Pglycoprotein in the inward-facing state. The Journal of biological chemistry. 2013; 288(26):19211-20. Epub 2013/05/10. doi: 10.1074/jbc.M113.450114 PMID: 23658020; PubMed Central PMCID: PMC3696692.
36. Pajeva IK, Globisch C, Wiese M. Comparison of the inward- and outward-open homology models and ligand binding of human P-glycoprotein. The FEBS journal. 2009; 276(23):7016-26. Epub 2009/11/03. doi: 10.1111/j.1742-4658.2009.07415.x PMID: 19878299.
37. Bessadok A, Garcia E, Jacquet H, Martin S, Garrigues A, Loiseau N, et al. Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins. The Journal of biological chemistry. 2011; 286(5):3552-69. Epub 2010/11/26. doi: 10.1074/jbc.M110. 155200 PMID: 21098040; PubMed Central PMCID: PMC3030360.
38. Gyimesi G, Ramachandran S, Kota P, Dokholyan NV, Sarkadi B, Hegedus T. ATP hydrolysis at one of the two sites in ABC transporters initiates transport related conformational transitions. Biochimica et biophysica acta. 2011; 1808(12):2954-64. Epub 2011/08/16. doi: 10.1016/j.bbamem.2011.07.038 PMID: 21840296.
39. Ivetac A, Sansom MS. Molecular dynamics simulations and membrane protein structure quality. European biophysics journal: EBJ. 2008; 37(4):403-9. Epub 2007/10/26. doi: 10.1007/s00249-007-0225-4 PMID: 17960373.
40. Chang G, Roth CB, Reyes CL, Pornillos O, Chen YJ, Chen AP. Retraction. Science. 2006; 314 (5807):1875. Epub 2006/12/23. doi: 10.1126/science.314.5807.1875b PMID: 17185584.
41. Liu Y, Yang Y, Qi J, Peng H, Zhang JT. Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. The Journal of pharmacology and experimental therapeutics. 2008; 326(1):33-40. Epub 2008/04/24. doi: 10.1124/jpet.108.138115 PMID: 18430864; PubMed Central PMCID: PMC2632310.
42. Locher KP, Lee AT, Rees DC. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science. 2002; 296(5570):1091-8. Epub 2002/05/11. doi: 10.1126/science. 1071142 PMID: 12004122.
43. Hohl M, Briand C, Grutter MG, Seeger MA. Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation. Nature structural & molecular biology. 2012; 19(4):395-402. Epub 2012/ 03/27. doi: 10.1038/nsmb.2267 PMID: 22447242.
44. Ward A, Reyes CL, Yu J, Roth CB, Chang G. Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(48):19005-10. Epub 2007/11/21. doi: 10.1073/pnas.0709388104 PMID: 18024585; PubMed Central PMCID: PMC2141898.
45. Csanady L, Chan KW, Nairn AC, Gadsby DC. Functional roles of nonconserved structural segments in CFTR's NH2-terminal nucleotide binding domain. The Journal of general physiology. 2005; 125(1):43-55. Epub 2004/12/15. doi: 10.1085/jgp.200409174 PMID: 15596536; PubMed Central PMCID: PMC2217481.
46. Aleksandrov AA, Kota P, Aleksandrov LA, He L, Jensen T, Cui L, et al. Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. Journal of molecular biology. 2010; 401 (2):194-210. Epub 2010/06/22. doi: 10.1016/j.jmb.2010.06.019 PMID: 20561529; PubMed Central PMCID: PMC4361937.
47. Ambudkar SV, Kim IW, Xia D, Sauna ZE. The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS letters. 2006; 580 (4):1049-55. Epub 2006/01/18. doi: 10.1016/j.febslet.2005.12.051 PMID: 16412422.
48. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature. 2006; 443 (7108):180-5. Epub 2006/09/01. doi: 10.1038/nature05155 PMID: 16943773.
49. Henriksen U, Fog JU, Litman T, Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. The Journal of biological chemistry. 2005; 280 (44):36926-34. Epub 2005/08/19. doi: 10.1074/jbc.M502937200 PMID: 16107343.
50. Ozvegy-Laczka C, Laczko R, Hegedus C, Litman T, Varady G, Goda K, et al. Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. The Journal of biological chemistry. 2008; 283 (38):26059-70. Epub 2008/07/23. doi: 10.1074/jbc.M803230200 PMID: 18644784; PubMed Central PMCID: PMC3258862.
51. Diop NK, Hrycyna CA. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry. 2005; 44(14):5420-9. Epub 2005/04/06. doi: 10.1021/bi0479858 PMID: 15807535.
52. Li YF, Polgar O, Okada M, Esser L, Bates SE, Xia D. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study. Journal of molecular graphics & modelling. 2007; 25(6):837-51. Epub 2006/10/10. doi: 10.1016/j.jmgm.2006. 08.005 PMID: 17027309.
53. Rutledge RM, Esser L, Ma J, Xia D. Toward understanding the mechanism of action of the yeast multidrug resistance transporter Pdr5p: a molecular modeling study. Journal of structural biology. 2011; 173(2):333-44. Epub 2010/11/03. doi: 10.1016/j.jsb.2010.10.012 PMID: 21034832; PubMed Central PMCID: PMC3026082.
54. Rosenberg MF, Bikadi Z, Chan J, Liu X, Ni Z, Cai X, et al. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure. 2010; 18(4):482-93. Epub 2010/04/20. doi: 10.1016/j.str.2010.01.017 PMID: 20399185; PubMed Central PMCID: PMC2858361.
55. Wang H, Lee EW, Cai X, Ni Z, Zhou L, Mao Q. Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry. 2008; 47(52):13778-87. Epub 2008/12/10. doi: 10.1021/bi801644v PMID: 19063604; PubMed Central PMCID: PMC2649121.
56. Tusnady GE, Simon I. The HMMTOP transmembrane topology prediction server. Bioinformatics. 2001; 17(9):849-50. Epub 2001/10/09. PMID: 11590105.
57. Dobson L, Remenyi I, Tusnady GE. CCTOP: a Consensus Constrained TOPology prediction web server. Nucleic acids research. 2015; 43(W1):W408-12. Epub 2015/05/07. doi: 10.1093/nar/gkv451 PMID: 25943549; PubMed Central PMCID: PMC4489262.
58. Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. The Journal of biological chemistry. 2002; 277(50):47980-90. Epub 2002/10/11. doi: 10. 1074/jbc.M207857200 PMID: 12374800.
59. Hou YX, Li CZ, Palaniyandi K, Magtibay PM, Homolya L, Sarkadi B, et al. Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport. Biochemistry. 2009; 48(38):9122-31. Epub 2009/08/21. doi: 10.1021/bi900675v PMID: 19691360; PubMed Central PMCID: PMC2770347.
60. Telbisz A, Ozvegy-Laczka C, Hegedus T, Varadi A, Sarkadi B. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein. The Biochemical journal. 2013; 450(2):387-95. Epub 2012/12/05. doi: 10.1042/BJ20121485 PMID: 23205634.
61. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute. 2006; 98(23):1739-42. Epub 2006/12/07. doi: 10.1093/jnci/djj469 PMID: 17148776.
62. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug metabolism and pharmacokinetics. 2012; 27(1):85-105. Epub 2011/11/30. PMID: 22123128.
63. Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmacogenomics and personalized medicine. 2014; 7:53-64. Epub 2014/02/14. doi: 10.2147/PGPM.S38295 PMID: 24523596; PubMed Central PMCID: PMC3921828.
64. Saranko H, Tordai H, Telbisz A, Ozvegy-Laczka C, Erdos G, Sarkadi B, et al. Effects of the gout-causing Q141K polymorphism and a CFTR DeltaF508 mimicking mutation on the processing and stability of the ABCG2 protein. Biochemical and biophysical research communications. 2013; 437(1):140-5. Epub 2013/06/27. doi: 10.1016/j.bbrc.2013.06.054 PMID: 23800412.
65. Woodward OM, Tukaye DN, Cui J, Greenwell P, Constantoulakis LM, Parker BS, et al. Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(13):5223-8. Epub 2013/03/16. doi: 10.1073/pnas.1214530110 PMID: 23493553; PubMed Central PMCID: PMC3612674.
66. Polgar O, Ediriwickrema LS, Robey RW, Sharma A, Hegde RS, Li Y, et al. Arginine 383 is a crucial residue in ABCG2 biogenesis. Biochimica et biophysica acta. 2009; 1788(7):1434-43. Epub 2009/05/02. doi: 10.1016/j.bbamem.2009.04.016 PMID: 19406100; PubMed Central PMCID: PMC4163909.
67. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer research. 2001; 61(18):6635-9. Epub 2001/09/18. PMID: 11559526.
68. Ni Z, Bikadi Z, Shuster DL, Zhao C, Rosenberg MF, Mao Q. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochemistry. 2011; 50(37):8057-66. Epub 2011/08/23. doi: 10.1021/bi200573t PMID: 21854076; PubMed Central PMCID: PMC3172388.
69. Telbisz A, Muller M, Ozvegy-Laczka C, Homolya L, Szente L, Varadi A, et al. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochimica et biophysica acta. 2007; 1768(11):2698-713. Epub 2007/07/31. doi: 10.1016/j.bbamem.2007.06.026 PMID: 17662239.
70. Storch CH, Ehehalt R, Haefeli WE, Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. The Journal of pharmacology and experimental therapeutics. 2007; 323(1):257-64. Epub 2007/07/27. doi: 10.1124/jpet.107.122994 PMID: 17652262.
71. Velamakanni S, Janvilisri T, Shahi S, van Veen HW. A functional steroid-binding element in an ATPbinding cassette multidrug transporter. Molecular pharmacology. 2008; 73(1):12-7. Epub 2007/12/21. doi: 10.1124/mol.108.038299 PMID: 18094074.
72. Gal Z, Hegedus C, Szakacs G, Varadi A, Sarkadi B, Ozvegy-Laczka C. Mutations of the central tyrosines of putative cholesterol recognition amino acid consensus (CRAC) sequences modify folding, activity, and sterol-sensing of the human ABCG2 multidrug transporter. Biochimica et biophysica acta. 2015; 1848(2):477-87. Epub 2014/12/03. doi: 10.1016/j.bbamem.2014.11.006 PMID: 25445676.
73. Hegedus C, Telbisz A, Hegedus T, Sarkadi B, Ozvegy-Laczka C. Lipid regulation of the ABCB1 and ABCG2 multidrug transporters. Advances in cancer research. 2015; 125:97-137. Epub 2015/02/03. doi: 10.1016/bs.acr.2014.10.004 PMID: 25640268.